Phase I evaluation of sequential doxorubicin + gemcitabine then ifosfamide + paclitaxel + cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Transitional Cell
AG is a well-tolerated and active regimen. Sequential chemotherapy with AG-ITP is also well tolerated, and phase II investigation at the highest dose level is ongoing.